[期刊]
  • 《World Journal of Clinical Oncology》 2024年8期

摘要 : Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irAEs),significa... 展开

作者 An-Jie Guo   Qing-Yuan Deng   Pan Dong   Lian Zhou   Lei Shi  
作者单位
期刊名称 《World Journal of Clinical Oncology 》
期刊英文名称 《世界临床肿瘤学杂志(英文)》
页码/总页数 P.1002-1020 / 19
语种/中图分类号 汉语 / R730.3  
关键词 Immunotherapy   Immune checkpoint inhibitors   Immune-related adverse events   Biomarkers   Cancers  
DOI 10.5306/wjco.v15.i8.1002
基金项目 Supported by The Fundamental Research Funds for the Central Universities,No.2019CDYGYB024;The National Natural Science Foundation of China,No.31300726;The Chongqing Primary and Middle School Innovation Talent Training Project,No.CY220113.
相关作者
相关关键词